23andMe founder Anne Wojcicki speaks during a House Committee on Oversight and Government Reform hearing in Washington, D.C., on June 10, 2025. Andrew Harnik | Getty Images Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals, … Read more
Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. … Read more
A view of the 23andMe headquarters in Sunnyvale, California, on March 25, 2025. Tayfun Coskun | Anadolu | Getty Images Regeneron Pharmaceuticals on Monday announced it will acquire “substantially all” of 23andMe’s assets for $256 million. The drugmaker participated in a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for … Read more
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters Shares of drugmakers fell on Wednesday after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. Shares of U.S.-based companies Eli Lilly, AbbVie, Bristol Myers Squibb and Regeneron all fell about 4% … Read more